

Cost minimization of a high-concentration Adalimumab biosimilar: The Greek Context

Rigopoulos P¹, Mortaki K¹, Stratopoulos A¹, Avgerinou M¹, Kougioumtzoglou I¹
¹Vianex S.A., Athens

EE623

Objective

- ❖ There is a plethora of adalimumab products available in Greece, including both the originator and several biosimilars.
- ❖ The introduction of a new high concentration adalimumab biosimilar (CT-P17), has the potential to minimize the costs of treatment in adalimumab-treated patients.
- ❖ The purpose of this study was to compare the costs associated with CT-P17 to other adalimumab products in Greece.

Methods

- ❖ A cost-minimization analysis (CMA) was developed to compare the costs of treating patients with CT-P17 to those of the reference product and available adalimumab biosimilars, from Greek third-party payer (EOPYY) perspective.
- ❖ Due to the different amount of drug used for each indication, the CMA result shows a cost comparison in each indication over a one-year period.
- ❖ The cost of CT-P17 was compared to other adalimumab products including the originator and all available biosimilars.
- ❖ The treatment dose and administration¹ schedule were used to calculate the total cost of a treatment for a five-year time horizon.
- ❖ Drug prices were obtained by the latest National Price bulletin.²

Results

CT-P17 had the lowest annual Drug Acquisition Cost among all biosimilars compared (Table 1). DAC of CT-P17 was on average 39% lower compared to the DACs of adalimumab and its biosimilars. Annual relative cost reduction of CT-P17 vs. originator was 53.5% (17,849€) regardless of the indication (Figure 1). Greater absolute cost reduction was observed in Hidradenitis suppurativa (33,318€ over 5-year time horizon). Compared to other biosimilars, CT-P17 was the most cost-minimizing option with cost reduction ranging from 20.2% to 43.3% depending on the comparing biosimilar and indication (Figure 2).

Table 1: Drug acquisition costs (€), per patient, per year

	Year 1	Year 2	Year 3	Year 4	Year 5
CT-P17	6.402	5.950	5.742	5.541	5.347
Humira	13.763	12.790	12.343	11.911	11.494
Amgevita	11.301	10.503	10.135	9.781	9.438
Hyrimoz	10.977	10.202	9.845	9.500	9.168
Hulio	9.851	9.155	8.835	8.525	8.227
Idacio	8.020	7.454	7.193	6.941	6.698
Imraldi	10.125	9.410	9.080	8.763	8.456
Halimatoz	10.977	10.202	9.845	9.500	9.168
Hefiya	10.977	10.202	9.845	9.500	9.168

Figure 1: Annual cost comparison between adalimumab biosimilars





Figure 2: Relative cost reduction between CT-P17 and other adalimumab biosimilars



Conclusion

The inclusion of CT-P17 as an alternative for the originator and other available biosimilars, is a cost-minimizing option from EOPYY perspective for the treatment of all adalimumab indications. Hence, the introduction of CT-P17 to the market has the potential to bring substantial savings to the Greek Healthcare System by reducing pharmaceutical costs of adalimumab-treated patients.

References

1. Yuflyma | European Medicines Agency. (n.d.). Retrieved October 19, 2022, from <https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma>
2. Greek Ministry of Health. (2022, June 27). *Official pricelist*. <https://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn/10612-epikairopoihs-deltioy-timwn-farmakwn-anthrwpinhs-xrhshs-me-enswmatwsh-dioikhtikwn-metabolwn>

